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Abstract 
Enzyme replacement therapy for Pompe disease received market authorization in 2006. To implement this costly treatment in the 
Netherlands in the most sensible way, a multidisciplinary expert committee was installed. We evaluated decision making in adult patients 
in relation to the European POmpe Consortium stop criteria. Of 125 adult Pompe patients, 111 started treatment; subsequently treatment 
stopped in 24 patients (21%). In 10 patients, treatment was discontinued for medical or personal reasons, as defined in the six stop criteria 
(median treatment duration: 2.1 years, range: 0.3–14.6 years). Three of these patients continued follow-up (follow-up: 1.3–8.0 years), these 
patients did not display a more rapid decline after discontinuation. In 14 of 24 patients, therapy ended at time of death. In 10 patients death 
was related to Pompe disease (median treatment duration: 7.2 years, range: 0.4–10.3 years). All 10 patients were severely affected at start 
of treatment, treatment had elicited positive effects in eight. The European POmpe Consortium guidelines worked well in decision making 
on stopping treatment. However, (re)evaluation of the rationale for continuation of treatment in advanced disease stage is not addressed. We 
suggest to add this to the treatment evaluation and to handle treatment decisions in a multidisciplinary expert team. 
© 2019 The Author(s). Published by Elsevier B.V. 
This is an open access article under the CC BY-NC-ND license. ( http://creativecommons.org/licenses/by-nc-nd/4.0/ ) 
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(. Introduction 
Pompe disease (glycogen storage disease type II or acid
altase deficiency, OMIM ID: 232300) is a rare inherited
etabolic and neuromuscular disorder, which presents as
 clinical spectrum, ranging from the rapidly progressive
lassic infantile form, to more slowly progressive phenotypes
n children and adults [1-5] . Enzyme replacement therapy
ERT) with alglucosidase alfa for Pompe disease, was in 2006
he first therapy for a neuromuscular disorder that received∗ Corresponding author. 
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Pompe disease: Evaluating the European POmpe Consortium stop criteria, Neuroarket authorization. In adults, ERT has shown to improve
r stabilize muscle strength, pulmonary function and daily life
ctivities, and has resulted in increased survival [6–13] . 
In the Netherlands, all patients with Pompe disease
re referred to the Center for Lysosomal and Metabolic
iseases of the Erasmus University Medical Center, the
ational designated center of expertise for Pompe disease.
o implement the costly therapy in our country in the
ost sensible way, a multidisciplinary expert committee was
nstalled to decide on starting and stopping of ERT. Our
enter contributed to the realization of the European POmpe
onsortium (EPOC) consensus recommendation for starting
nd stopping ERT in 2017, and implemented these criteria
n our expert committee consultation [14] . The consensuscess article under the CC BY-NC-ND license. 
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I  guidelines imply that all patients undergo a fixed battery
of assessments to evaluate the effects of the therapy [15] .
Reasons to consider discontinuation of ERT comprise infusion
associated reactions (IARs), high neutralizing antibody titers,
non-compliance to the treatment and/or assessment protocol,
the patient’s wish to stop ERT, other life-threatening illness
or the lack of any clinical stabilization or improvement in the
first 2 years of treatment. The guidelines advise to consider
restart of ERT if a patient deteriorates faster after ERT
discontinuation than during ERT. 
In our experience, decisions regarding stopping ERT are
often difficult, even when the EPOC stop criteria are met,
particularly because ERT is currently the only available
treatment for Pompe disease. Moreover, since the effects
of stopping ERT on disease course are largely unknown,
both physicians and patients usually fear for a relatively
rapid decline after discontinuation of ERT, particularly when
treatment has been effective. 
In this study, we specifically focus on adult patients
who discontinued therapy and evaluate the motives, clinical
course, and the applicability of the EPOC treatment guidelines
on stopping ERT. Furthermore, to gain insight in treatment
decisions in patients with advanced Pompe disease or
comorbidity, we evaluate the clinical course, treatment effect
and causes of death of patients in whom ERT ended at
time of death, with special regards to whether we should
have considered discontinuation of ERT earlier in the course
of disease in some. We aim to address important clinical
dilemmas regarding discontinuation of ERT in adults with
Pompe disease, with the intention to add to the use and
optimization of the present EPOC treatment guidelines. 
2. Methods 
2.1. Study design 
We analyzed data of patients who participated in a
prospective, cohort study which includes all patients with
Pompe disease in the Netherlands, which started in 2004. We
also included patients who started to receive ERT even before
that. The Center for Lysosomal and Metabolic Diseases,
Erasmus MC University Medical Center, Rotterdam serves
as the single reference center for Pompe patients with a
confirmed diagnosis. The diagnosis was confirmed by enzyme
analysis in leukocytes and/or fibroblasts and by mutation
analysis. Patients were included in the current study if they
discontinued ERT for any reason, between start of ERT and
January 1st 2017. All patients gave their written informed
consent. 
2.2. Procedures 
Clinical assessments were performed on a regular basis
(every 3–6 months) and included the following parameters: Please cite this article as: H.A. van Kooten, L. Harlaar and N.A.M.E. van der B
Pompe disease: Evaluating the European POmpe Consortium stop criteria, Neuro.2.1. Skeletal muscle strength and muscle function 
Skeletal muscle strength was measured by manual muscle
esting using the Medical Research Council (MRC) grading
cale (range 0–5) [16 , 17] . Muscle groups tested comprise
he neck flexors, neck extensors, shoulder abductors, shoulder
dductors, shoulder exorotators, shoulder endorotators, elbow
exors, elbow extensors, hip flexors, hip extensors, hip
bductors, hip adductors, knee flexors and knee extensors. 
Muscle function was assessed using the Quick Motor
unction Test (QMFT), which evaluates 16 motor skills that
re specifically challenging for patients with Pompe disease
18] . This was recorded on video. For the MRC and QMFT,
um-scores were derived as described previously [19] . If
alues for three or more items were missing, no sum-score
as calculated. The use of a wheelchair was registered at
ach visit. 
.2.2. Pulmonary function 
Forced vital capacity (FVC) was measured in upright and
upine positions according to ATS/ERS standards. Results
ere expressed as a percentage of the predicted normal values
20] . The use of mechanical ventilation was registered at each
isit. 
.3. ERT multidisciplinary expert committee 
With the reimbursement of ERT in the Netherlands in
006, a multidisciplinary expert committee was installed at
rasmus MC, to decide on starting and stopping of ERT in
atients with Pompe disease. The team comprises various
edical experts (i.e. pediatricians, neurologists, internists),
 hospital pharmacist, a medical ethicist, a molecular
iologist, research physicians (Ph.D. students), and nurses.
he committee has an independent chair. Every newly
iagnosed patient with Pompe disease is evaluated by this
eam, to determine whether ERT should be started. Decisions
re based on careful consideration of the patients’ clinical
ondition, comorbidity and ability to comply to the treatment
rotocol, following the EPOC guidelines [14] . For treated
atients, the effects of ERT are evaluated after the first two
ears of treatment by evaluating a set of outcome measures
MRC, FVC, QMFT), including video recordings of the
atient performing the QMFT. The committee also advises
n possible discontinuation of ERT. Reasons to advise on
iscontinuation are (lack of) efficacy, new comorbidity that
argely interferes with the effects of ERT, high neutralizing
ntibody titers or infusion associated reactions. 
. Results 
In total, 125 adult patients with Pompe disease were
valuated and included in the ongoing study. Fig. 1 shows
n overview of the study population. In 111 of 125 (88.8%)
atients ERT was started. Of this group, 24 patients stopped
eceiving ERT (21.6%) and qualified for the current analyses.
n 10/24 patients treatment was discontinued for medical oreek et al., Discontinuation of enzyme replacement therapy in adults with 
muscular Disorders, https:// doi.org/ 10.1016/ j.nmd.2019.11.007 
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Fig. 1. Flowchart of the study population. 
Overview of 125 adult Pompe patients participating in our nationwide, prospective, cohort study. N : number of patients; ERT: enzyme replacement therapy; 
IARs: infusion associated reactions. 
Table 1 
Applicability of the European POmpe consortium (EPOC) criteria for 
stopping ERT on the patients who discontinued ERT in our cohort. 
EPOC stop criteria N in our cohort 
1. The patient suffers from severe infusion-associated 
reactions that cannot be managed properly. 
4 
2. High antibody titers are detected that significantly 
counteract the effect of ERT. 
1 
3. The patient wishes to stop ERT. 2 
4. The patient does not comply with regular infusions or 
yearly clinical assessments. 
1 
5. The patient has another life-threatening illness that is 
in an advanced stage, where treatment to sustain life 
is inappropriate. 
1 
6. There is no indication that skeletal muscle function 
and/or respiratory function have stabilized or improved 
in the first 2 years after start of treatment, as assessed 
using clinical assessments. 
1 
ERT: enzyme replacement therapy; N : number of patients. 
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e  ersonal reasons (group 1). In 14/24 patients, ERT ended
hen the patient died (group 2). 
.1. Group 1: reasons for discontinuation of ERT for 
edical or personal reasons 
In Table 1 , the reasons for discontinuation of ERT for
he patients in our cohort are summarized, listed according
o the six EPOC stop criteria. In four patients (3.6% of all
reated patients), ERT was discontinued because of infusion
ssociated reactions (IARs) (stop criterion 1). Usually, IARsPlease cite this article as: H.A. van Kooten, L. Harlaar and N.A.M.E. van der B
Pompe disease: Evaluating the European POmpe Consortium stop criteria, Neuroan be managed by decelerating the infusion schedule and/or
tarting pre-medication with clemastine and hydrocortisone. 
owever, in these four patients, IAR symptoms and/or side
ffects of pre-medication remained unacceptable for the
atient and therefore ERT was discontinued. Most frequent
ARs were hyperthermia/fever and chills, (generalized) 
xanthema, hypertension and chest pain. In one patient ERT
as discontinued because high antibodies that counteracted 
he effect of ERT were detected (stop criterion 2) [21] . Two
atients experienced the burden of the treatment as too high
nd requested to stop ERT, after 3 months and 5.9 years
f treatment (stop criterion 3). In one patient we decided to
iscontinue ERT after 9 months, because of non-compliance
o the treatment protocol (stop criterion 4). In one patient
RT was stopped because treatment for B-cell lymphoma
as started (stop criterion 5). One patient discontinued ERT
ecause of deterioration of clinical condition despite therapy
stop criterion 6). The characteristics of these 10 patients are
ummarized in Table 2 (Group 1). Median treatment duration
as 2.1 years (range 0.3–14.6 years). 
.1.1. Group 1: disease course after discontinuation of ERT 
In seven patients, no follow up data after discontinuation
f ERT were available. This was either because patients chose
o stop clinical assessments after discontinuation, or because
he patient’s condition hampered clinical assessments. The
isease course in these seven patients is shown in Fig. 2 (A).
n four patients (Patients 1a, 1c, 1e and 1g) ERT had been
ffective, improving or stabilizing motor and/or pulmonaryeek et al., Discontinuation of enzyme replacement therapy in adults with 
muscular Disorders, https:// doi.org/ 10.1016/ j.nmd.2019.11.007 
4 H.A. van Kooten, L. Harlaar and N.A.M.E. van der Beek et al. / Neuromuscular Disorders xxx (xxxx) xxx 
ARTICLE IN PRESS 
JID: NMD [m5+; January 3, 2020;21:57 ] 
Please cite this article as: H.A. van Kooten, L. Harlaar and N.A.M.E. van der Beek et al., Discontinuation of enzyme replacement therapy in adults with 
Pompe disease: Evaluating the European POmpe Consortium stop criteria, Neuromuscular Disorders, https:// doi.org/ 10.1016/ j.nmd.2019.11.007 
H.A. van Kooten, L. Harlaar and N.A.M.E. van der Beek et al. / Neuromuscular Disorders xxx (xxxx) xxx 5 
ARTICLE IN PRESS 
JID: NMD [m5+; January 3, 2020;21:57 ] 
Table 2 
Patient characteristics. 
Group 1 Group 2 
Discontinuation of ERT ( N = 10) Deceased patients ( N = 14) 
Pompe related Non-Pompe related 
(N = 10) (N = 4) 
Gender, male N (%) 5 (50) 10 (100) 2 (50) 
Current age in years 52.6 (40.8–83.5) a – –
Age at death in years 45.9 (30.7–56.2) b 65.4 (51.8–77.7) 69.1 (62.0–74.8) 
Follow up time in years 7.1 (0.7–11.7) 7.2 (0.4–10.3) 3.8 (1.3–6.0) 
Age at start of ERT 42.7 (28.7–74.0) 56.5 (51.0–76.0) 66.0 (61.0–70.0) 
Disease duration at start of ERT in years 11.5 (5.3–29.1) 27.3 (15.6–46.7) 39.4 (30.5–40.0) 
Treatment duration in years 2.1 (0.3–14.6) 7.2 (0.4–10.3) 2.7 (0.2–4.4) 
Disability at start of ERT, N (%) 
No wheelchair or mechanical ventilation 4 (40) 1 (10) 1 (25) 
Wheelchair use 4 (40) – 1 (25) 
Ventilation use – – –
Both use of wheelchair and ventilation 2 (20) 9 (90) 2 (50) 
All data are median (range) unless otherwise specified. N : number of patients; ERT: enzyme replacement therapy. 
a N = 7, other patients deceased. 
b N = 3, patients died 1.0–3.3 years after discontinuation of ERT. 
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Tunction. Patient 1b deteriorated despite ERT. Two patients
ere treated too short to determine the effects of ERT
Patients 1d and 1f). Three patients (Patients 1d, 1e and 1f)
ied 1.0–3.3 years after discontinuation of ERT. Their median
ge at death was 45.9 years (range 30.7–56.2 years), causes
f death were respiratory insufficiency, autoimmune hepatitis
nd lymphoma. 
Three patients continued follow-up after discontinuation 
f ERT (1.3–8.0 years), their disease course is shown in
ig. 2 (B) (Patients 1h, 1i, and 1j). Patient 1h displayed
igh sustained antibody titers that counteracted the effect
f treatment, explaining the observed treatment failure and
ARs [21] . Patient 1i showed a stable disease course
uring treatment, but had to discontinue ERT because of
nmanageable IARs. Patient 1j displayed stabilization of
otor function and improvement of pulmonary function, but
equested to stop because of the burden of the treatment.
ndividual natural disease progression in these three patients
ould not be estimated due to limited data on disease course
rior to treatment with ERT. Previous studies on natural
isease progression at group level in our cohort showed an
stimated yearly decline in pulmonary function (FVC) in
itting and supine position of 1.0% and 1.3%, and in muscle
trength (MRC) of 1.3% [22] . For the QMFT, no estimated
early decline was calculated previously. We compared the
isease course after treatment cessation in these three specific
atients with estimated natural progression rates and observedig. 2. Clinical course of patients who discontinued ERT. 
linical course of patients who discontinued ERT without follow up data after dis
vailable follow up data after discontinuation (B). Each line represents an individu
vailable are depicted. All outcome measures are expressed as percentages of pre
or each individual patient. The dotted lines indicate estimated natural progressio
atients were the following: clinical deterioration and IARs in the presence of h
reatment (Patient 1j). ERT: Enzyme Replacement Therapy; MRC: Medical Rese
est. 
Please cite this article as: H.A. van Kooten, L. Harlaar and N.A.M.E. van der B
Pompe disease: Evaluating the European POmpe Consortium stop criteria, Neuro stable disease course, or a slow decline similar to the
stimated progression rate. No unexpected (rapid) decline in
ny of the outcome measures was observed in these patients.
.2. Group 2: deceased patients 
In 14 patients, treatment with ERT ended when the
atient died. We distinguished patients with a Pompe
elated cause of death, and patients with causes of
eath probably not related to Pompe disease. The
haracteristics of these patients, are summarized in Table 2
Group 2). 
In 10 of 14 deceased patients (71.4%) the cause of death
as, certainly or most likely, related to Pompe disease. All
0 patients were male. Their disease history and causes of
eath are shown in the lower part of Fig. 3 (Patients 2a–
j). Nine of these 10 patients were already wheelchair and
entilator dependent when ERT was started (shortly after
eimbursement in 2006). The duration of treatment with ERT
aried widely from 0.4 to 10.3 years. The clinical course of
hese patients can be found in the Appendix. Eight patients
ere treated for more than 2 years, all showed improvement
r stabilization of at least one outcome measure (MRC,
VC and/or QMFT). The most common cause of death was
cute-on-chronic respiratory insufficiency ( n = 7). Five of
hese patients were dependent on invasive ventilation, in most
atients an obstruction or unintended disconnection of thecontinuation (A) and clinical course of patients who discontinued ERT with 
al patient. For each outcome measure, only the patients of whom data were 
dicted normal values. The X depicts the moment of discontinuation of ERT 
n rate at group level [22] . The reasons for discontinuation of ERT in these 
igh sustained antibody titers (Patient 1h), IARs (Patient 1i) and burden of 
arch Council; FVC: Forced Vital Capacity; QMFT: Quick Motor Function 
eek et al., Discontinuation of enzyme replacement therapy in adults with 
muscular Disorders, https:// doi.org/ 10.1016/ j.nmd.2019.11.007 
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Fig. 3. Pompe disease history of deceased patients. 
Each bar represents an individual patient, including cause of death. The lower part shows the patients who (most likely) deceased as a consequence of Pompe 
disease (Patients 2a–2j). In the upper part, the patients who did not decease as a consequence of Pompe disease are displayed (Patients 2k–2n). ∗ Arterial 
dissection has been related to storage of glycogen in smooth muscle cells of the arterial wall. Therefore it cannot be ruled out that the aortic dissection was 
related to Pompe disease [23] . ERT: enzyme replacement therapy. 
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rtracheal tube caused acute respiratory failure. Three patients
died from sepsis, caused by severe decubitus as a result of
immobilization, which we considered a lethal complication of
Pompe disease. Median age at death was 65.4 years (range
51.8–77.7 years). 
Four patients deceased from causes other than Pompe
disease. The characteristics of these patients are shown in
Table 2 . The upper part of Fig. 3 shows the Pompe disease
history and causes of death of these patients (Patients 2k–2n).
Three patients died from malignancies (colon cancer, adrenal
cancer and breast cancer). Median age at death was 69.1
years. Median duration of treatment was 2.7 years (range
0.2–4.4). The clinical course of these patients is shown in
the Appendix. All patients showed a good response to ERT
(stabilization or improvement of motor and/or respiratory
function). 
4. Discussion 
In our study, all 10 of 111 treated patients who
discontinued ERT met at least one of the EPOC stop
criteria, indicating that the current EPOC guidelines work
well in decision making on stopping ERT. Concerns about
disease progression arise when discontinuation of ERT has
to be considered for specific reasons (i.e. IARs, serious
comorbidity), particularly when treatment has been effective.
Long-term follow-up data after discontinuation of ERT werePlease cite this article as: H.A. van Kooten, L. Harlaar and N.A.M.E. van der B
Pompe disease: Evaluating the European POmpe Consortium stop criteria, Neurovailable of three patients in our cohort (follow-up: 1.3–8.0
ears), in these patients a rapid decline after discontinuation
as not observed. A Swiss study addresses the effect of
emporary discontinuation of ERT in seven Pompe disease
ho had to stop ERT due to reimbursement issues [24] . In
hese patients, duration of treatment (3.1–61.1 months) and
uration of treatment cessation (3.1–59.3 months) were quite
ariable, hampering direct comparison with the three patients
ho discontinued ERT in our cohort. The FVC rate of decline
uring cessation in the Swiss patients varied from −0.3 to
2.0% per month (median −1.4%). Muscle strength (MRC)
id not decline significantly, although 6MWT did. Natural
isease progression in our cohort is estimated −1.0% per
ear for FVC in upright position and −1.3% per year for
RC. The decline reported in the Swiss patients will at least
n part represent natural disease progression, but to which
xtent remains unknown, as natural course data of these
atients are not reported. Interestingly, clinical symptoms
tabilized or improved after restarting ERT, also during long
erm follow up (36 months) [25] . This underlines the note
n the EPOC stop criteria that restarting of ERT can be
onsidered if the disease deteriorates faster after stopping
han during treatment. Another study described four patients
ho discontinued ERT due to fatigue, inefficacy of ERT and
ncompliance, reporting a stable disease course after treatment
essation (with unknown follow up) [26] . This study did not
efer to expected natural disease course either. eek et al., Discontinuation of enzyme replacement therapy in adults with 
muscular Disorders, https:// doi.org/ 10.1016/ j.nmd.2019.11.007 
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 In 14 patients, treatment ended at time of death, 10 of
hese patients died as a consequence of Pompe disease.
n the majority of these patients, ERT was continued until
eath. We therefore evaluated treatment effect in these
atients, with special regards to whether we should have
onsidered discontinuation of ERT earlier in the course
f these severely affected patients. All 10 patients who
eceased as a consequence of Pompe disease started ERT
hortly after reimbursement in 2006, when already being in
n advanced stage of the disease ( Fig. 3 ). Eight patients
isplayed improvement or stabilization of motor and/or
espiratory function after start of ERT. Our findings support
he previously reported beneficial effect of ERT in advanced
ompe disease and the EPOC recommendation that ERT can
e started also in severely affected patients [27 , 28] . 
Sudden death from acute-on-chronic respiratory failure was
eported in the majority ( n = 7) of the patients who died
rom Pompe disease. Since these patients showed a positive
esponse to ERT, there has never been a reason to consider
iscontinuation of ERT earlier in the course of disease.
owever, in our cohort one patient clinically deteriorated
uring ERT, which restrained him to visit our clinic for almost
8 months. Since this patient could not comply to yearly
linical assessments anymore (EPOC stop criterion 4), we
ould have decided to discontinue ERT earlier in this patient.
The EPOC consensus states that if there is no effect
f ERT after the first two years of treatment, ERT in
rinciple should be discontinued (stop criterion 6). In our
ractice, a growing number of patients is on ERT well
ver two years, also in a more advanced disease stage. We
dvise (re)evaluation of the efficacy of and rationale for
ontinuation of ERT during long-term treatment, particularly
n patients in an advanced stage of the disease. In the current
POC guideline, start criterion 5 (“The patient should have
esidual skeletal and respiratory muscle function which is
onsidered functionally relevant and clinically important for
he patient to maintain or improve”) aims to refrain from
tarting ERT in severely affected patients. However, potential
iscontinuation of ERT in severely affected patients during
ong-term treatment is not addressed. To implement this re-
valuation, we propose to consider to stop ERT in a patient
ho has insufficient residual skeletal and respiratory function
eft to be functionally relevant. 
Our multidisciplinary approach in decision making on
tarting and stopping ERT has several advantages. Since
he majority of these experts do not have a direct
elationship with the patient regarding the prescription of
RT, this allows an objective process of treatment decision
aking. The multidisciplinary basis of the team ensures
areful consideration of all relevant clinical, pharmacological,
iological and ethical aspects in decision making in every
atient and justifies the handling of this costly therapy to
ociety. 
The strength of our study is the standardized follow up
f a large cohort of patients over a long period of time.
oreover, our population encompasses all known adults with
 confirmed diagnosis of Pompe disease in the Netherlands.Please cite this article as: H.A. van Kooten, L. Harlaar and N.A.M.E. van der B
Pompe disease: Evaluating the European POmpe Consortium stop criteria, Neurohe most important limitation is the small number of patients
f whom long term follow up data after discontinuation of
RT were available. 
Our study evaluates our long-standing experience in
reating adults with Pompe disease, focusing on decision
aking in stopping ERT. In three patients, who discontinued
RT in accordance with the stop criteria, we did not observe
 more rapid decline after treatment discontinuation, which is
ften a concern of both patients and physicians. However,
s the number of patients with long-term follow-up data
fter discontinuation of ERT was small, additional studies are
eeded. In general, the current EPOC guidelines work well in
ecision making on stopping ERT. However, (re)evaluation of
he rationale for continuation of ERT in (far) advanced disease
tage is not addressed in the current criteria. We recommend
o handle treatment decisions in a multidisciplinary expert
eam, to ensure objective and careful consideration of all
elevant medical and non-medical aspects of the disease and
ts treatment, including quality of life, in every single patient.
rasmus MC Pompe expert committee 
.L. van der Pol (Chair), E. Brusse, I.A.M. Ditters, L.
arlaar, M.J. Hoogendijk-Boon, H.H. Huidekoper, E.J.O.
ompanje, A. Oskam, W.W.M. Pijnappel, B.J. Sibbles, J.J.A.
an den Dorpel, N.A.M.E. van der Beek, J.M.P. van der Hout,
. van der Kuy, A.T. van der Ploeg, P.A. van Doorn, H.A.
an Kooten, A.G. Vulto, M.A.E.M. Wagenmakers. 
upplementary materials 
Supplementary material associated with this article can be
ound, in the online version, at doi:10.1016/j.nmd.2019.11. 
07 . 
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